A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer

References

• Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009; 9(1):29-33; PMID:19299237; http://dx.doi.org/10.3816/CBC.2009.n.005
   PubMed Web of Science ®Google Scholar
• Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006; 210(1):49-58; PMID:16823893; http://dx.doi.org/10.1002/path.2021
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Jr., Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85(16):1327-33; PMID:8340945; http://dx.doi.org/10.1093/jnci/85.16.1327
   PubMed Web of Science ®Google Scholar
• Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pego A, Chan A, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31(20):2586-92; PMID:23733761; http://dx.doi.org/10.1200/JCO.2012.46.2408
   PubMed Web of Science ®Google Scholar
• Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30(21):2615-23; PMID:22665533; http://dx.doi.org/10.1200/JCO.2010.34.5579
   PubMed Web of Science ®Google Scholar
• Nechushtan H, Vainer G, Stainberg H, Salmon AY, Hamburger T, Peretz T. A phase 1/2 of a combination of Cetuximab and Taxane for "triple negative" breast cancer patients. Breast 2014; 23(4):435-8; PMID:24836394; http://dx.doi.org/10.1016/j.breast.2014.03.003
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, et al. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol 2014; 25(8):1570-7; PMID:24827135; http://dx.doi.org/10.1093/annonc/mdu183
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364(3):205-14; PMID:21208101; http://dx.doi.org/10.1056/NEJMoa1011418
   PubMed Web of Science ®Google Scholar
• Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28(7):1145-53; PMID:20100965; http://dx.doi.org/10.1200/JCO.2009.22.4725
   PubMed Web of Science ®Google Scholar
• Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga JY. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011; 22(4):848-56; PMID:20924076; http://dx.doi.org/10.1093/annonc/mdq461
   PubMed Web of Science ®Google Scholar
• Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 2009; 124(6):1457-62; PMID:19065658; http://dx.doi.org/10.1002/ijc.24090
   PubMed Web of Science ®Google Scholar
• Chia J, Ang P, See H, Wong Z, Soh L, Yay Y, Wong N. Triple- negative metatstatic/reurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy. J Clin Oncol 2007; 25; (18S, Abstract # 1086)
   Google Scholar
• Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K, Freeman DJ, Johnson CW, Krishnan K, Johnson D. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. J Thor Oncol 2013; 8(12):1510-8; PMID:24389433; http://dx.doi.org/10.1097/JTO.0b013e3182a7d1da
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27(8):1160-7; PMID:19204204; http://dx.doi.org/10.1200/JCO.2008.18.1370
   PubMed Web of Science ®Google Scholar
• Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2013; 137(2):483-92; PMID:23242585; http://dx.doi.org/10.1007/s10549-012-2378-9
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10(16):5367-74; PMID:15328174; http://dx.doi.org/10.1158/1078-0432.CCR-04-0220
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100(14):8418-23; PMID:12829800; http://dx.doi.org/10.1073/pnas.0932692100
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21):2492-502; PMID:16757721; http://dx.doi.org/10.1001/jama.295.21.2492
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25(22):3230-7; PMID:17664471; http://dx.doi.org/10.1200/JCO.2006.10.5437
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360(14):1408-17; PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019
   PubMed Web of Science ®Google Scholar
• Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014; 5(2):125-33; PMID:24829859; http://dx.doi.org/10.5306/wjco.v5.i2.125
   PubMedGoogle Scholar
• Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28(6):911-7; PMID:20100966; http://dx.doi.org/10.1200/JCO.2009.21.9618
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373(9674):1525-31; PMID:19410716; http://dx.doi.org/10.1016/S0140-6736(09)60569-9
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy JA. Highlights in metastatic breast cancer from the 2013 San Antonio Breast Cancer Symposium (SABCS). Clin Adv Hematol Oncol 2014; 12(3 Suppl 7):3-17; PMID:24870974
   PubMedGoogle Scholar
• Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29(10):1252-60; PMID:21383283; http://dx.doi.org/10.1200/JCO.2010.28.0982
   PubMed Web of Science ®Google Scholar
• Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17(21):6905-13; PMID:22028489; http://dx.doi.org/10.1158/1078-0432.CCR-11-0288
   PubMed Web of Science ®Google Scholar